Business Context and Reporting Period
This Form 8-K is a Current Report filed by Oncocyte Corporation (trading symbol: OCX) on July 8, 2024. The filing addresses a specific corporate governance matter regarding compliance with Nasdaq listing rules. Note: The request metadata referenced "Insight Molecular Diagnostics Inc.", but the filing text explicitly identifies the registrant as Oncocyte Corporation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is non-financial in nature and focuses solely on regulatory compliance status.
Material Changes
The report details a temporary noncompliance and subsequent restoration of compliance with Nasdaq Listing Rules:
- Noncompliance Event: The passing of director Alfred D. Kingsley on April 25, 2024, caused the Board to fall below the required majority of independent directors and the Audit Committee to fall below the required three independent members.
- Resolution: The Company regained compliance effective July 1, 2024, following a determination that existing director and newly appointed audit committee member Andrew Arno qualifies as "independent."
- Regulatory Status: Nasdaq confirmed the Company's subsequent compliance with Rules 5605(b)(1) and 5605(c)(2) on July 8, 2024.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary risk addressed was the potential delisting or failure to satisfy continued listing standards due to board composition, which has been resolved.
Investor Verification Checklist
- Verify the current composition of the Board of Directors and Audit Committee to confirm the independence status of Andrew Arno.
- Review the prior Form 8-K filed on July 5, 2024, for the initial disclosure of the independence determination.
- Confirm that no other pending governance issues exist that could impact Nasdaq listing status.